Discovery NMCT 670
Feature | Dave Fornell

Diagnostic imaging is generally considered safe and noninvasive, so it is extremely unusual for a patient to die from injuries received from a scanner. However, this was the case in early June when a patient was killed because a portion of a SPECT/CT scanner fell during the scan at the James J. Peters VA Medical Center in the Bronx, N.Y.

Home September 13, 2013
Home
Feature | Dave Fornell

Vascular closure devices have a definite niche in areas where they were not originally intended but have found frequent off-label use because of their utility.

Home September 13, 2013
Home
X0000_Abbott_ProGlide_w_Call_outs
Feature | Patrick Antoun, M.D., and Jeffrey A. Breall, M.D., Ph.D.

Vascular closure devices (VCD) were first introduced in the early 1990s with a goal to achieve quick hemostasis, thus reducing patients’ stay in the hospital (shorter time to ambulation) as well as faster turnover times for cardiac catheterization laboratories.

Home September 13, 2013
Home
Feature | Dave Fornell

The use of 3-D echo can help improve the accuracy and reproducibility of cardiac quantification. The technology has the advantage of removing the inter-operator variability by imaging whole volume datasets of the heart, so specific images or organ views can be extracted and reconstructed in any position, similar to CT or MRI datasets. Also, because a volumetric dataset is captured, exam times can be shortened, instead of spending time trying to get just the right angle for a 2-D slice view. Cardiac quantification can also be improved by measuring the entire heart or ventricle, rather than just slices of it. New software also automates this quantification.

Home September 13, 2013
Home
Technology

Atherotech Diagnostics Lab has added three new genetic tests to its cardiometabolic test offering: warfarin sensitivity, Plavix sensitivity and the thrombophilia risk test.

Home September 13, 2013
Home
News

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee will review two new technologies to help treat heart failure (HF) Oct. 8-9, 2013.

Home September 13, 2013
Home
News

Abbott promised preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack. [1] The test could be particularly beneficial for women, who may have different presenting symptoms and are often under-diagnosed. [2] The study, which is being conducted by researchers at the University of Edinburgh, is evaluating Abbott's Architect Stat High Sensitive Troponin-I (hsTnI) test, which received CE mark in January 2013.

Home September 12, 2013
Home
LINC Study Resuscitation Devices Defibrillator CPR Lucas Chest Compression
Feature

The main results of the large randomized LINC study, which compared the effectiveness of the Lucas mechanical chest compression system to high quality manual chest compressions, were presented at the European Society of Cardiology Congress in Amsterdam, the Netherlands. The LINC study showed similar short-term survival rates for Lucas (23.6%) and manual (23.7%) chest compressions. At six-months, 8.5% of the patients treated with LUCAS were alive with good neurological outcomes compared to 7.6% in the manual group.

Home September 11, 2013
Home
X0000_Direct Flow_TAVR valve_top_closed_0
Feature

Direct Flow Medical Inc. announced the first patient enrollment in the U.S. SALUS clinical trial. The trial will study the Direct Flow Medical Transcatheter Aortic Heart Valve System, which encompasses a distinctive transcatheter aortic heart valve with a metal-free frame and flexible, low-profile delivery system designed to eliminate aortic regurgitation. The device is intended to improve the long-term survivability of aortic stenosis patients by resolving the clinical issues associated with current commercial valves.

Home September 11, 2013
Home
News

UltraSPECT announced that MaineHealth, a family of hospitals and medical centers throughout Maine, has selected the UltraSPECT Xpress.Cardiac and Xpress3.Cardiac solutions as part of the organization’s strategy for reducing nuclear medicine (NM) dose and complying with the American Society of Nuclear Cardiology (ASNC) final guidelines effective Jan. 1, 2014. Maine Medical Partners (MMP) – MaineHealth Cardiology in South Portland is one of ten facilities within MaineHealth that is installing the product, with others scheduled to continue roll out before the end of 2013.

Home September 11, 2013
Home
News

In patients with atrial fibrillation, delayed enhancement magnetic resonance imaging (DE-MRI) performed before ablative treatment can stage the degree of damaged heart tissue (atrial fibrosis) and help predict whether treatment will be successful or not, according to results of Delayed Enhancement — MRI determinant of successful Catheter Ablation of Atrial Fibrillation (DECAAF) trial.

Home September 10, 2013
Home
News

At RSNA 2013, Sony will be showing a works-in-progress medical recorder, the HVO-500MD (without DVD optical drive) and the HVO-550MD (with DVD optical drive). These models are designed specifically for medical recording.

Home September 10, 2013
Home
Technology

Toshiba is introducing a new Aquilion One platform at RSNA 2013. The new Aquilion One family allows providers to more precisely choose the system that fits their needs today while giving them an upgrade path for the future.

Home September 10, 2013
Home
Technology

September 9, 2013 — Toshiba’s new Aquilion Prime is a versatile, scalable and patient-friendly computed tomography (CT) system. The system’s technologies are built for the clinical and financial needs of users both in the present and future.

Home September 09, 2013
Home
News

September 9, 2013 — Keystone Heart, a company in the development of cerebral protection devices for interventional cardiology and cardiac surgery procedures, announced its TriGuard cerebral protection device has received CE mark, enabling the company to commercially market the TriGuard in Europe and other territories.

Home September 09, 2013
Home
Subscribe Now